Malignant Melanoma | Disease Landscape & Forecast | G7 | 2024
Immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab ± ipilimumab, and nivolumab plus relatlimab) and BRAF/MEK inhibitor combinations (e.g., vemurafenib plus cobimetinib) have greatly changed the treatment of malignant melanoma in both the resectable and metastatic settings, and more drugs with novel mechanisms of action are on the horizon (e.g., lifileucel, an adoptive cell therapy approved in February 2024). In this report, we discuss the current and future treatment of malignant melanoma and opportunities for development that remain, such as novel agents that specifically target the BRAF wild-type unresectable or metastatic population.
Questions answered
- How large are the clinically and commercially relevant malignant melanoma drug-treatable populations? How will drug treatment rates change, if at all, over the forecast period?
- What is the current treatment landscape in malignant melanoma?
- Which currently approved drugs are the most prescribed and why?
- Which drugs in late-phase development are poised to change the treatment landscape for malignant melanoma and how? What sales / uptake could these drugs secure in the malignant melanoma market?
- What are the key drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period
Content highlights
Geographies: United States, EU5, Japan
Primary research: 19 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research
Epidemiology: incidence of malignant melanoma by country, segmented by BRAF mutation status, disease stage, and line of therapy
Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2033, segmented by brands / generics / biosimilars and epidemiological subpopulations.
Emerging therapies: Phase 3: 8 drugs; Phase 2: 2 drugs; coverage of select early-phase products.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
